Hematocrit Test Devices Market Size & Share 2026-2035

Hematocrit Test Devices Market Size

The high market growth is attributed to the increasing prevalence of blood disorders, growing geriatric population, and advancements in point-of-care testing, among other contributing factors. Hematocrit test devices are diagnostic instruments used to measure the proportion of red blood cells (RBCs) in a patient’s blood sample, expressed as a percentage of total blood volume. These devices are commonly used in hospitals, diagnostic laboratories, and point-of-care settings to assess conditions such as anemia, dehydration, and other blood-related disorders.

The major players in the global hematocrit test devices market are Danaher, Sysmex, Abbott, Siemens Healthineers, and Roche. These companies maintain their competitive position through ongoing product innovation, global market presence, and substantial investment in research and development.

The market has increased from USD 3.6 billion in 2022 and reached to USD 3.8 billion in 2024, with a historic growth rate of 2.6%. The market growth was driven by the rising prevalence of anemia and blood disorders, increasing demand for routine blood diagnostics, growing adoption of hematology analyzers in hospitals and diagnostic laboratories, and expanding healthcare infrastructure worldwide.

Moreover, the rising prevalence of blood disorders including anemia, polycythemia, and sickle cell disease increases the demand for hematocrit testing. For instance, according to the World Health Organization (WHO), anemia affects about 1.62 billion people globally, representing 24.8% of the population.

Similarly, the Centers for Disease Control and Prevention (CDC) reports that sickle cell disease affects approximately 100,000 Americans, with 1 in 365 Black or African American births having the condition. Hence, these medical conditions require continuous monitoring of hematocrit levels, which drives the need for accurate and accessible testing equipment.

Furthermore, continuous innovations in hematology analyzers, microfluidic technologies, and automated testing platforms are improving the accuracy, speed, and efficiency of hematocrit measurement. Modern devices offer compact designs, digital integration, and improved sample processing capabilities. These advancements are encouraging healthcare facilities to adopt advanced hematocrit testing systems.

The global hematocrit test devices market was valued at USD 3.9 billion in 2025. The market is expected to reach from USD 4 billion in 2026 to USD 6.1 billion in 2035, growing at a CAGR of 4.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

Hematocrit Test Devices Market Trends

The market is witnessing significant growth driven by growing adoption of point-of-care (POC) hematocrit testing, increasing integration of digital connectivity and data management systems, advancements in automated and high-throughput hematology analyzers, and emergence of microfluidic and advanced detection technologies, among other factors, are boosting industry growth.

• One of the most prominent trends is the rapid shift toward point-of-care hematocrit testing devices. Portable and handheld analyzers allow healthcare professionals to conduct tests directly at the patient’s bedside, in emergency rooms, ambulances, or outpatient clinics. These devices provide faster diagnostic results and reduce dependence on centralized laboratories. The ability to deliver rapid results significantly improves clinical decision-making in trauma care, anemia screening, and surgical monitoring.
  
• Modern hematocrit testing devices are increasingly equipped with digital connectivity features such as Bluetooth, Wi-Fi, and cloud-based data management systems. These technologies enable seamless integration with laboratory information systems (LIS) and electronic health records (EHR). As a result, clinicians can access patient results in real time, improving workflow efficiency and remote patient monitoring. This digital integration also supports telemedicine and decentralized healthcare models.
  
• Further, there is a strong trend toward miniaturization of diagnostic devices, leading to the development of lightweight handheld hematocrit meters. These devices provide rapid results, often within seconds and are particularly useful in remote clinics, rural healthcare settings, and mobile health units. The demand for portable solutions is rising due to the global push for decentralized healthcare and faster diagnostics outside traditional laboratory environments.
  

Hematocrit Test Devices Market Analysis

Based on product, the hematocrit test devices market is segmented into instruments and reagents and consumables. The instruments segment has asserted its dominance in the market by securing a significant market share of 58.3% in 2025 owing to the increasing adoption of automated hematology analyzers and hematocrit testing instruments in hospitals and diagnostic laboratories for accurate and high-throughput blood analysis. The segment is expected to exceed USD 3.4 billion by 2035, growing at a CAGR of 4.3% during the forecast period.

• The growing preference for rapid diagnostics is driving the demand for portable hematocrit testing instruments in emergency departments, ambulatory care centers, and outpatient clinics. These devices allow healthcare professionals to obtain quick hematocrit results without relying on centralized laboratories. Faster results support timely treatment decisions, particularly in trauma, surgery, and critical care settings.
  
• Moreover, the rising global prevalence of anemia, chronic kidney disease, and other hematological conditions is increasing the need for reliable hematocrit measurement. Healthcare providers require accurate diagnostic instruments to monitor red blood cell concentration and evaluate patient health status. This growing disease burden is contributing to the increased adoption of hematocrit testing instruments across healthcare facilities.
  
• The reagents and consumables segment held a revenue of USD 1.6 billion in 2025, with projections indicating a steady expansion at a CAGR of 5.4% from 2026 to 2035. The segment is driven by the high testing frequency of hematology diagnostics, which requires continuous replenishment of reagents, cartridges, and microcapillary tubes for routine blood analysis. Additionally, the growing volume of diagnostic tests and increasing patient screening programs are further boosting recurring demand for these consumables across laboratories and healthcare facilities.
  

Based on modality, the hematocrit test devices market is classified into laboratory-based testing and point-of-care (POC) testing. The laboratory-based testing segment accounted for USD 2.6 billion market revenue in 2025 and is anticipated to grow at a CAGR of 4.6% between the 2026 to 2035 period.

• Laboratory-based hematocrit testing devices are known for their high precision and reliability in providing accurate results. Healthcare professionals rely on these tests to diagnose conditions such as anemia, polycythemia, and dehydration, where precise hematocrit levels are essential for treatment planning.
  
• Additionally, as the complexity of health conditions increases and the demand for detailed diagnostic testing grows, laboratory-based testing remains the gold standard for hematocrit analysis. Healthcare providers require highly accurate data for more complex patient profiles, which can be achieved through lab-based instruments. This is expected to drive growth in this segment of the market.
  
• The point-of-care (POC) testing segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 5.3% over the forecast period. The segment is driven by the growing need for rapid diagnostic results in emergency and critical care settings, enabling immediate clinical decision-making. In addition, increasing adoption of decentralized healthcare and mobile diagnostic services is supporting the use of hematocrit testing outside traditional laboratory environments.
  

Based on application, the hematocrit test devices market is classified into anemia, congenital heart diseases, polycythemia vera, and other applications. The anemia segment dominated the market with a revenue share of 45.8% in 2025 and is expected to reach USD 2.7 billion within the forecast period.

• Anemia, especially iron-deficiency anemia, is one of the most common blood disorders globally, particularly affecting women, children, and the elderly. The high number of anemia cases increases the demand for reliable and accurate hematocrit testing to monitor and diagnose the condition.
  
• Further, the growing awareness about anemia and its impact on health has led to more regular screenings. Early detection through hematocrit tests helps in timely intervention and treatment, reducing complications associated with anemia. This drives the need for hematocrit test devices in clinical and point-of-care settings. This is anticipated to boost the segmental growth in the market.
  
• The congenital heart diseases segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 5.5% over the forecast period. The congenital heart diseases segment is driven by the increasing need for regular blood monitoring in pediatric and neonatal patients to assess oxygen-carrying capacity and blood viscosity levels. Additionally, advancements in neonatal and pediatric cardiac care are increasing the use of hematocrit testing during diagnosis, treatment monitoring, and post-surgical management.
  
• The polycythemia vera segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 5.1% over the forecast period. The segment is driven by the growing need for continuous monitoring of elevated red blood cell levels to manage disease progression and treatment effectiveness. Additionally, increased clinical awareness and improved diagnostic screening for myeloproliferative disorders are supporting the demand for hematocrit testing in patient management.
  

Based on end use, the hematocrit test devices market is classified into hospitals, diagnostic laboratories, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 52.6% in 2025 and is expected to reach USD 3.2 billion within the forecast period.

• Hospitals handle a large volume of patients requiring routine blood tests for diagnosis and monitoring. Hematocrit testing is commonly included in complete blood count (CBC) tests to evaluate red blood cell levels. The high frequency of laboratory testing in hospitals drives continuous demand for hematocrit test devices.
  
• Hospitals frequently treat patients suffering from anemia, chronic kidney disease, and cardiovascular conditions that require regular hematocrit monitoring. Hematocrit testing helps physicians evaluate disease severity and track treatment outcomes. The growing burden of these chronic conditions is increasing the use of hematocrit testing devices in hospitals.
  
• The diagnostic laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 5.3% over the forecast period. The segmental growth is driven by the increasing outsourcing of routine blood testing by hospitals and clinics to specialized laboratory service providers. Additionally, the rising consolidation of diagnostic lab networks and expansion of high-volume testing facilities is boosting the demand for hematocrit testing devices.
  

• The ambulatory surgical centers segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 4% over the forecast period. The segment is driven by the growing shift toward outpatient and minimally invasive surgical procedures that require quick pre-operative blood assessments. Additionally, the increasing number of same-day surgeries is boosting the need for rapid hematocrit testing to ensure patient safety and procedural readiness.
  

North America Hematocrit Test Devices Market

North America dominated the market with the highest market share of 40.1% in 2025.

• The U.S. hematocrit test devices industry was valued at USD 1.36 billion and USD 1.39 billion in 2022 and 2023, respectively. The market size reached USD 1.45 billion in 2025, growing from USD 1.42 billion in 2024, and is anticipated to grow at a CAGR of 4.3% from 2026 to 2035.
  
• The region benefits from a highly developed healthcare system with well-established hospitals, diagnostic laboratories, and research institutions. These facilities are equipped with advanced hematology analyzers capable of performing high-volume testing with high accuracy. Healthcare providers prioritize early diagnosis and continuous monitoring of blood parameters. This well-developed infrastructure significantly supports the adoption of hematocrit testing devices.
  
• North America hosts several leading diagnostic and medical technology companies that develop and commercialize hematology analyzers and point-of-care testing devices. Continuous investments in research and development enable these companies to introduce innovative hematocrit testing solutions. The presence of these key players accelerates technological advancements and improves device accessibility. This competitive environment helps drive regional market growth.
  

Europe Hematocrit Test Devices Market

Europe market accounted for USD 1.1 billion in 2025 and is anticipated to witness lucrative growth.

• European healthcare systems emphasize preventive care and early disease detection. Many countries conduct routine health screenings that include complete blood count testing, which measures hematocrit levels. These programs help detect conditions such as anemia and blood abnormalities at an early stage. As preventive healthcare initiatives expand, the demand for hematocrit testing devices continues to rise.
  
• Diagnostic laboratories across Europe are increasingly adopting automated hematology analyzers to improve efficiency and reduce manual workload. Automation enables laboratories to process large numbers of samples with higher accuracy and faster turnaround times. Hematocrit testing is integrated into these automated systems as part of routine blood analysis. This trend toward laboratory automation is driving the demand for advanced hematocrit testing instruments.
  

Asia Pacific Hematocrit Test Devices Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 6.2% during the analysis timeframe.

• Asia Pacific accounts for a large share of the global population and has a high prevalence of anemia, particularly in developing countries. Nutritional deficiencies, pregnancy-related anemia, and chronic diseases contribute to the increasing need for blood diagnostics. Governments and healthcare providers are emphasizing anemia screening programs. This growing disease burden is significantly increasing the demand for hematocrit testing devices.
  
• Countries such as China, India, and Southeast Asian nations are investing heavily in expanding hospitals, clinics, and diagnostic laboratories. The development of new healthcare facilities is improving access to diagnostic testing services. As hospitals upgrade laboratory capabilities, the adoption of hematocrit testing instruments is increasing. This infrastructure expansion is a key growth driver in the region.
  

Latin America Hematocrit Test Devices Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• Many Latin American countries are investing in strengthening diagnostic healthcare capabilities to improve disease detection and management. Governments and healthcare institutions are expanding laboratory services and upgrading diagnostic equipment. Hematocrit testing plays an important role in routine blood analysis and disease diagnosis. These improvements in diagnostic infrastructure are driving the demand for hematocrit testing devices.
  
• Nutritional deficiencies remain a major health concern in several Latin American countries, leading to a high prevalence of anemia among children and women. Hematocrit testing is widely used to diagnose and monitor anemia cases. Public health programs focusing on nutritional improvement and anemia screening have increased blood testing rates. This trend is supporting market growth for hematocrit testing devices.
  

Middle East & Africa Hematocrit Test Devices Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Countries in the Middle East, particularly the UAE and Saudi Arabia, are making significant investments in modernizing healthcare infrastructure. New hospitals, specialized clinics, and diagnostic laboratories are being established to improve healthcare services. These facilities require advanced laboratory equipment, including hematology analyzers. As a result, the demand for hematocrit testing devices is increasing across the region.
  
• Many regions in Africa have limited access to centralized healthcare facilities and diagnostic laboratories. Portable hematocrit testing devices allow healthcare workers to conduct blood tests in rural and underserved areas. International health organizations and government programs are promoting point-of-care diagnostics to improve healthcare accessibility. This demand for mobile diagnostic solutions is driving market adoption.
  

Hematocrit Test Devices Market Share

The hematocrit test devices industry is moderately consolidated and characterized by the presence of several global diagnostic equipment manufacturers competing on technological innovation, product accuracy, and integrated hematology testing capabilities.

Companies are focusing on expanding their hematology analyzer portfolios, improving automation, and enhancing point-of-care testing solutions to meet the growing demand for rapid blood diagnostics. Continuous investments in research and development, along with strategic collaborations and product launches, are enabling manufacturers to strengthen their market positions and broaden their global presence.

Competition is largely driven by product performance, testing speed, reliability, and the ability to integrate hematocrit measurement with complete blood count (CBC) systems. Key players include Danaher, Sysmex, Abbott, Siemens Healthineers, and Roche, collectively accounting for ~65% of the total market share.

These companies leverage strong global distribution networks, established brand recognition, and advanced diagnostic technologies to maintain competitive advantage. Additionally, emerging players and regional manufacturers are focusing on cost-effective hematocrit testing devices and portable diagnostic solutions to capture opportunities in developing markets.

Hematocrit Test Devices Market Companies

A few of the prominent players operating in the hematocrit test devices industry include:

• A. Menarini
• Abbott
• BIO-RAD
• Boule
• Danaher
• Diatron
• EKF Diagnostics
• HORIBA Medical
• Mindray
• NIHON KOHDEN
• Nova Biomedical
• Roche
• SENSA CORE
• Siemens Healthineers
• Sysmex

• Danaher, through Beckman Coulter Diagnostics, offers highly automated hematology analyzers with advanced workflow automation and high-throughput testing capabilities. Its strong global service network and integrated laboratory solutions enhance efficiency and reliability in hematocrit testing.
  
• Sysmex is known for its technologically advanced hematology analyzers that deliver high precision and rapid blood parameter analysis, including hematocrit measurement. The company’s strong R&D capabilities and specialized focus on hematology diagnostics strengthen its leadership in laboratory testing.
  
• Abbott provides hematocrit testing through its point-of-care diagnostic platforms such as the i-STAT system, enabling rapid blood analysis in critical care and emergency settings. Its portable testing solutions support faster clinical decision-making and decentralized diagnostics.
  

Hematocrit Test Devices Industry News

• In January 2026, HORIBA obtained CE IVDR certification for its Yumizen H500 CRP benchtop hematology analyzer, which enabled simultaneous 5-part differential blood analysis and rapid C-Reactive Protein (CRP) whole blood measurement. The launch is anticipated to strengthen the company’s hematology diagnostics portfolio by integrating inflammation markers with routine blood testing. This development is expected to support the market by enhancing multi-parameter testing efficiency and expanding advanced hematology analyzer adoption in clinical laboratories.
  
• In July 2024, EKF Diagnostics announced the launch of its new Biosen C-Line, an advanced version of its industry-leading rapid hematocrit analyzer. It was designed to enhance usability with a new color touch screen and advanced connectivity, enabling seamless integration with hospital and laboratory IT systems. This innovation ensures quick and secure availability of patient results to clinicians. With this launch, the company strengthened its position in the hematocrit testing market, offering improved workflow efficiency and attracting healthcare facilities seeking advanced, connected solutions for enhanced patient care.
  

The hematocrit test devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
  • Hematocrit test analyzer
  • Hematocrit test meter
• Reagents and consumables

Market, By Modality

• Laboratory-based testing
• Point-of-care (POC) testing

Market, By Application

• Anemia
• Congenital heart diseases
• Polycythemia vera
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE